{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:29:19Z","timestamp":1778531359364,"version":"3.51.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Renal cell carcinoma (RCC) is the seventh most common cancer in humans, of which clear cell renal cell carcinoma (ccRCC) accounts for the majority. Recently, although there have been significant breakthroughs in the treatment of ccRCC, the prognosis of targeted therapy is still poor. Leukemia inhibitory factor (LIF) is a pleiotropic protein, which is overexpressed in many cancers and plays a carcinogenic role. In this study, we explored the expression and potential role of LIF in ccRCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The expression levels and prognostic effects of the LIF gene in ccRCC were detected using TCGA, GEO, ICGC, and ArrayExpress databases. The function of LIF in ccRCC was investigated using a series of cell function approaches. LIF-related genes were identified by weighted gene correlation network analysis (WGCNA). GO and KEGG analyses were performed subsequently. Cox univariate and LASSO analyses were used to develop risk signatures based on LIF-related genes, and the prognostic model was validated in the ICGC and E-MTAB-1980 databases. Then, a nomogram model was constructed for survival prediction and validation of ccRCC patients. To further explore the drug sensitivity between LIF-related genes, we also conducted a drug sensitivity analysis based on the GDSC database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mRNA and protein expression levels of LIF were significantly increased in ccRCC patients. In addition, a high expression of LIF has a poor prognostic effect in ccRCC patients. LIF knockdown can inhibit the migration and invasion of ccRCC cells. By using WGCNA, 97 LIF-related genes in ccRCC were identified. Next, a prognostic risk prediction model including eight LIF-related genes (TOB2, MEPCE, LIF, RGS2, RND3, KLF6, RRP12, and SOCS3) was developed and validated. Survival analysis and ROC curve analysis indicated that the eight LIF-related-gene predictive model had good performance in evaluating patients\u2019 prognosis in different subgroups of ccRCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study revealed that LIF plays a carcinogenic role in ccRCC. In addition, we firstly integrated multiple LIF-related genes to set up a risk-predictive model. The model could accurately predict the prognosis of ccRCC, which offers clinical implications for risk stratification, drug screening, and therapeutic decision.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.934128","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:29:56Z","timestamp":1659504596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Elevated expression of LIF predicts a poor prognosis and promotes cell migration and invasion of clear cell renal cell carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenting","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyu","family":"lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShengZhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G","article-title":"The Heidelberg classification of renal cell tumours","volume":"183","author":"Kovacs","year":"1997","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1016\/j.celrep.2018.06.032","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2020.07.009","article-title":"Kidney cancer: An overview of current therapeutic approaches","volume":"47","author":"Chowdhury","year":"2020","journal-title":"Urologic Clinics North America"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200305000-00005","article-title":"Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma","volume":"27","author":"Cheville","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1040740303","article-title":"Differentiation of a cell line of myeloid leukemia","volume":"74","author":"Ichikawa","year":"1969","journal-title":"J Cell Physiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/j.1460-2075.1987.tb02742.x","article-title":"Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF)","volume":"6","author":"Gearing","year":"1987","journal-title":"EMBO J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.813428","article-title":"Identification of UBE2I as a novel biomarker in ccRCC based on a Large-scale CRISPR-Cas9 screening database and immunohistochemistry","volume":"9","author":"Li","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an r package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: a cancer single-cell state atlas","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12015-011-9261-7","article-title":"LIF-dependent signaling: New pieces in the Lego","volume":"8","author":"Mathieu","year":"2012","journal-title":"Stem Cell Rev Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.14800\/ccm.877","article-title":"The regulation of leukemia inhibitory factor","volume":"2","author":"Yue","year":"2015","journal-title":"Cancer Cell Microenviron"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garc\u00eda","year":"2019","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1038\/ncomms6218","article-title":"LIF negatively regulates tumour-suppressor p53 through Stat3\/ID1\/MDM2 in colorectal cancers","volume":"5","author":"Yu","year":"2014","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63428","article-title":"Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance","volume":"123","author":"Liu","year":"2013","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.04.003","article-title":"Targeting LIF\/LIFR signaling in cancer","volume":"9","author":"Viswanadhapalli","year":"2022","journal-title":"Genes Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1130-6","article-title":"Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring","volume":"569","author":"Shi","year":"2019","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00912","article-title":"Identification and validation of an immunological expression-based prognostic signature in breast cancer","volume":"11","author":"Pei","year":"2020","journal-title":"Front Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00005-021-00605-w","article-title":"Leukemia inhibitory factor: A potential biomarker and therapeutic target in pancreatic cancer","volume":"69","author":"Wrona","year":"2021","journal-title":"Archivum immunol therapiae experimentalis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/nyas.14466","article-title":"Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway","volume":"1484","author":"Bian","year":"2021","journal-title":"Ann New York Acad Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2008.00935.x","article-title":"Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma","volume":"35","author":"Chen","year":"2009","journal-title":"J Obstetrics gynaecol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.18632\/oncotarget.1772","article-title":"LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.1038\/s41598-020-68158-0","article-title":"Immunization against leukemia inhibitory factor and its receptor suppresses tumor formation of breast cancer initiating cells in BALB\/c mouse","volume":"10","author":"Ghanei","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.30.4.977","article-title":"Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression","volume":"30","author":"Kamohara","year":"2007","journal-title":"Int J Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4482","article-title":"Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K\/AKT-dependent mcl-1 activation","volume":"6","author":"Morton","year":"2015","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.001","article-title":"Leukemia inhibitory factor (LIF)","volume":"26","author":"Nicola","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0","article-title":"Activation of STAT proteins and growth control","volume":"23","author":"Bromberg","year":"2001","journal-title":"BioEssays News Rev Molecular Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.8272873","article-title":"Association and activation of jak-tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components","volume":"263","author":"Stahl","year":"1994","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.47.30136","article-title":"Gp130-mediated signal transduction in embryonic stem cells involves activation of jak and ras\/mitogen-activated protein kinase pathways","volume":"271","author":"Ernst","year":"1996","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.6.2846","article-title":"Essential role of STAT3 for embryonic stem cell pluripotency","volume":"96","author":"Raz","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.7871433","article-title":"Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors","volume":"267","author":"Stahl","year":"1995","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1042\/bj3350557","article-title":"Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression","volume":"335","author":"Schaper","year":"1998","journal-title":"Biochem J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05343-11","article-title":"Ribosome synthesis-unrelated functions of the preribosomal factor Rrp12 in cell cycle progression and the DNA damage response","volume":"31","author":"Dosil","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4062-2","article-title":"RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells","volume":"37","author":"Choi","year":"2016","journal-title":"Tumour Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.812009","article-title":"Validating RRP12 expression and its prognostic significance in HCC based on data mining and bioinformatics methods","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.07.022","article-title":"Taking rho GTPases to the next level: the cellular functions of atypical rho GTPases","volume":"313","author":"Aspenstr\u00f6m","year":"2007","journal-title":"Exp Cell Res"},{"key":"B41","article-title":"Epigenetic modification of RhoE expression in gastric cancer cells","volume":"25","author":"Chen","year":"2011","journal-title":"Oncol Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25568","article-title":"Rnd3\/RhoE is down-regulated in hepatocellular carcinoma and controls cellular invasion","volume":"55","author":"Grise","year":"2012","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20243","article-title":"Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis","volume":"64","author":"Bektic","year":"2005","journal-title":"Prostate"},{"key":"B44","article-title":"A pancreatic cancer-specific expression profile","volume":"13","author":"Gress","year":"1996","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9457-x","article-title":"Overexpression of RhoE has a prognostic value in non-small cell lung cancer","volume":"14","author":"Zhang","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20090129","article-title":"Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer","volume":"30","author":"Jiang","year":"2010","journal-title":"Biosci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2016.1277007","article-title":"Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells","volume":"29","author":"Cacan","year":"2017","journal-title":"J chemother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.10.088","article-title":"Regulator of G-protein signaling 2 (RGS2) in cardiology and oncology","volume":"179","author":"Patan\u00e8","year":"2015","journal-title":"Int J Cardiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15433","article-title":"RGS2 suppresses melanoma growth via inhibiting MAPK and AKT signaling pathways","volume":"41","author":"Lin","year":"2021","journal-title":"Anticancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41467-019-09116-x","article-title":"A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma","volume":"10","author":"Syafruddin","year":"2019","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0217","article-title":"Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread","volume":"65","author":"Narla","year":"2005","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2009.07.008","article-title":"BTG\/TOB factors impact deadenylases","volume":"34","author":"Mauxion","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jcp.21919","article-title":"The mammalian anti-proliferative BTG\/Tob protein family","volume":"222","author":"Winkler","year":"2010","journal-title":"J Cell Physiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25110","article-title":"Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma","volume":"116","author":"Shen","year":"2015","journal-title":"J Cell Biochem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00610-12","article-title":"Tob2 inhibits peroxisome proliferator-activated receptor \u03b32 expression by sequestering smads and C\/EBP\u03b1 during adipocyte differentiation","volume":"32","author":"Takahashi","year":"2012","journal-title":"Mol Cell Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0188-z","article-title":"Structural basis of 7SK RNA 5'-\u03b3-phosphate methylation and retention by MePCE","volume":"15","author":"Yang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/or.2020.7864","article-title":"Long non\u2212coding RNA ST8SIA6\u2212AS1 promotes the migration and invasion of hypoxia\u2212treated hepatocellular carcinoma cells through the miR\u2212338\/MEPCE axis","volume":"45","author":"Zhang","year":"2021","journal-title":"Oncol Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.934128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:30:03Z","timestamp":1659504603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.934128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":57,"alternative-id":["10.3389\/fonc.2022.934128"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.934128","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"article-number":"934128"}}